

DAFTAR PUSTAKA

- Alfarizi, R. (2015). HUBUNGAN TEKANAN DARAH DENGAN PENINGKATAN TEKANAN INTRAOKULI PADA PASIEN GLAUKOMA DI RSUD. DR. H. ABUL MOELOEK TAHUN. *Jurnal Ilmu Kedokteran Dan Kesehatan*, 2(4).
- Ashaye, A., Ashaolu, O., Komolafe, O., Ajayi, B. G. K., Olawoye, O., Olusanya, B., & Adeoti, C. (2013). Prevalence and Types of Glaucoma Among an Indigenous African Population in Southwestern Nigeria. *Investigative Ophthalmology & Visual Science*, 54(12), 7410–7416. <https://doi.org/10.1167/IOVS.13-12698>
- Asyifa, A. (2015). *Penilaian Penyakit dan Tingkat Risiko serta Faktor yang Berhubungan dengan Hipertensi pada Masyarakat Binaan KPKM Buaran FKIK UIN Syarif Hidayatullah FKIK UIN Syarif Hidayatullah Jakarta tahun 2015*.
- Avany, S. A. (2021). *Hubungan Hipertensi dengan Peningkatan Tekanan Intraokular di Rumah Sakit Khusus Mata Medan Baru Tahun 2021*.
- Badran, D., Abreu, P., & Restivo, M. T. (2022). Blood Pressure Measurement. *Proceedings of the 2019 5th Experiment at International Conference, Exp.at 2019*, 476–480. <https://doi.org/10.1109/EXPAT.2019.8876538>
- Beatrice Alberta, I., Chandra Sarsono, M., & Kuswidyati, C. (n.d.). *Glaucoma and Dry Eye Syndrome Impact on Quality of Life: What We Know?* <https://doi.org/10.51542/ijscia.v3i3.33>
- Blumberg, D., Skaat, A., & Liebmann, J. M. (2015). Emerging risk factors for glaucoma onset and progression. *Progress in Brain Research*, 221, 81–101. <https://doi.org/10.1016/BS.PBR.2015.04.007>
- Buck, C. (2017). *2018 ICD-10-CM Standard Edition-E-Book*.
- Cho, H. kyung, & Kee, C. (2014). Population-based glaucoma prevalence studies in Asians. *Survey of Ophthalmology*, 59(4), 434–447. <https://doi.org/10.1016/J.SURVOPHTHAL.2013.09.003>
- Chua, J., Chee, M. L., Chin, C. W. L., Tham, Y. C., Tan, N., Lim, S. H., Aung, T., Cheng, C. Y., Wong, T. Y., & Schmetterer, L. (2019). Inter-relationship between ageing, body mass index, diabetes, systemic blood pressure and intraocular pressure in Asians: 6-year longitudinal study. *British Journal of Ophthalmology*, 103(2), 196–202. <https://doi.org/10.1136/BJOPHTHALMOL-2018-311897>
- Daiber, H. F., & Gnugnoli, D. M. (2023). Visual Acuity. *Handbook of Visual Display Technology*, 1, 93–99. https://doi.org/10.1007/978-3-540-79567-4_2.1.3
- Direktorat P2PTM. (2013). *Pedoman Teknis Penemuan dan Tatalaksana Hipertensi*. Kementerian Kesehatan Republik Indonesia.
- Dizayang, F., Bambang, H., & Purwoko, M. (2020). Karakteristik Penderita Glaukoma di Rumah Sakit Muhammadiyah Palembang Periode Januari 2017-April 2018. *Journal of Health Sciences*, 13(01), 66–73. <https://doi.org/10.33086/JHS.V13I01.1146>
- Dorland, W. A. N., Dimanti, A., & Arfan, A. (2010). *Kamus Kedokteran Dorland* (32nd ed.). EGC.

- Efriza, E., Zainun, Z., & Inaldo, R. (2023). GAMBARAN FAKTOR RISIKO GLAUKOMA PRIMER PADA LANSIA DI RSUP DR. M. DJAMIL PADANG TAHUN 2017-2019. *Nusantara Hasana Journal*, 2(8), 301–313.
- Gabb, G. (2020). What is hypertension? *Australian Prescriber*, 43(4), 108–109. <https://doi.org/10.18773/AUSTPRESCR.2020.025>
- Gessese, G. W., & Damji, K. F. (2013). Advanced Glaucoma: Management Pearls. *Middle East African Journal of Ophthalmology*, 20(2), 131. <https://doi.org/10.4103/0974-9233.110610>
- Harrison, D. G., Coffman, T. M., & Wilcox, C. S. (2021). Pathophysiology of Hypertension. *Circulation Research*, 128, 847–863. <https://doi.org/10.1161/CIRCRESAHA.121.318082>
- Hirasawa, K., Shoji, N., Morita, T., & Shimizu, K. (2013). A modified glaucoma staging system based on visual field index. *Graefe's Archive for Clinical and Experimental Ophthalmology*, 251(12), 2747–2752. <https://doi.org/10.1007/s00417-013-2490-5>
- Ilyas, S., & Yulianti, S. R. (2014). *Ilmu Penyakit Mata* (5th ed.). Badan Penerbit FKUI.
- Ishikawa, M., Sawada, Y., Sato, N., & Yoshitomi, T. (2011). Risk factors for primary open-angle glaucoma in japanese subjects attending community health screenings. *Clinical Ophthalmology*, 5(1), 1531–1537. <https://doi.org/10.2147/OPHTH.S26049>
- Kim, H. J., Sung, M. S., & Park, S. W. (2023). Factors Associated with Visual Acuity in Advanced Glaucoma. *Journal of Clinical Medicine* 2023, Vol. 12, Page 3076, 12(9), 3076. <https://doi.org/10.3390/JCM12093076>
- Kim, K. E., & Park, K. H. (2016). Update on the prevalence, etiology, diagnosis, and monitoring of normal-tension glaucoma. *Asia-Pacific Journal of Ophthalmology*, 5(1), 23–31. <https://doi.org/10.1097/APO.0000000000000177>
- Lam, D., Lee, J., Jonas, J., Leung, C., Park, K. H., Sit, A., & Ritch, R. (2016). Glaucoma: Today and tomorrow. *Asia-Pacific Journal of Ophthalmology*, 5(1), 2–4. <https://doi.org/10.1097/APO.0000000000000184>
- Lusiana, N., Widayanti, L. P., Mustika, I., & Andiarna, F. (2019). Korelasi Usia dengan Indeks Massa Tubuh, Tekanan darah Sistol-Diastol, Kadar Glukosa, Kolesterol, dan Asam Urat. *Journal of Health Science and Prevention*, 3(2), 101–108. <https://doi.org/10.29080/JHSP.V3I2.242>
- Lusthaus, J., & Goldberg, I. (2019). Current management of glaucoma. *Medical Journal of Australia*, 210(4), 180–187. <https://doi.org/10.5694/MJA2.50020>
- Magder, S. (2018). The meaning of blood pressure. *Critical Care (London, England)*, 22(1). <https://doi.org/10.1186/S13054-018-2171-1>
- Mahendra, B. I., Gustianty, E., & Rifada, R. M. (2022). KARAKTERISTIK KLINIS GLAUKOMA PRIMER SUDUT TERTUTUP DI PUSAT MATA NASIONAL RUMAH SAKIT MATA CICENDO PADA TAHUN 2020. *Jurnal Kedokteran Dan Kesehatan : Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya*, 9(2), 235–244. <https://doi.org/10.32539/jkk.v9i2.16963>
- Matsuura, M., Hirasawa, K., Murata, H., & Asaoka, R. (2015). The Relationship Between Visual Acuity and the Reproducibility of Visual Field Measurements

- in Glaucoma Patients. *Investigative Ophthalmology & Visual Science*, 56(9), 5630–5635. <https://doi.org/10.1167/IOVS.15-17576>
- McMonnies, C. W. (2017). Glaucoma history and risk factors. *Journal of Optometry*, 10(2), 71–78. <https://doi.org/10.1016/J.OPTOM.2016.02.003>
- Nasikun, S. E., & Thjan, R. (2023). ANALISIS PENGARUH JENIS KELAMIN DAN KEDALAMAN BILIK MATA DEPAN TERHADAP KEJADIAN GLAUKOMA AKUT. *Biomedika*, 15(1), 91–95. <https://doi.org/10.23917/biomedika.v15i1.2292>
- Nislawati, R., Taufik, A., Zainal, F., Ismail, A., Waspodo, N., Kasim, F., Aunul, A. M., & Gunawan, K. (2021). Role of hypertension as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. *BMJ Open Opth*, 6, 798. <https://doi.org/10.1136/bmjophth-2021-000798>
- Nugraheni, F. R., Pangestuti, D. R., & Nungraheni, S. A. (2018). Hubungan Asupan Mineral, Indeks Massa Tubuh Dan Persentase Lemak Tubuh Terhadap Tekanan Darah Wanita Usia Subur (Studi di Wilayah Kerja Puskesmas. *Jurnal Kesehatan Masyarakat (Undip)*, 6(5), 350–360.
- Nursalamah, M. (2020). *Laporan Kasus Diagnosis dan Tatalaksana Glaukoma Kongenital*.
- Nuyen, B., & Mansouri, K. (2015). Fundamentals and advances in tonometry. *Asia-Pacific Journal of Ophthalmology*, 4(2), 66–75. <https://doi.org/10.1097/APO.0000000000000118>
- PERDAMI, Soemantri, I., Prahasta, A., Nurwasis, Rahmi, F. L., Oktariana, V. D., Firdalia, Waspodo, N., Ekantini, R., Dewi, M., Gustianty, E., Rahardjo, Kusumadjaja, I. M. A., Effendi, M., Komaratih, E., Primitasari, Y., Rifada, M., Astrianda, Dewi, A. T., ... Djamal, Z. E. (2018). *Pedoman Nasional Pelayanan Kedokteran Glaukoma*. PERDAMI.
- Pileggi, C., Papadopoli, R., De Sarro, C., Nobile, C. G. A., & Pavia, M. (2021). Obesity, Blood Pressure, and Intraocular Pressure: A Cross-Sectional Study in Italian Children. *Obesity Facts*, 14(2), 169–177. <https://doi.org/10.1159/000514096>
- Pratama, B. A., & -, Dr. S. E. S. M. (2019). *Hubungan Hipertensi dengan Tekanan Intraokuler pada Pasien Poli Mata RS Umum Sarila Husada Sragen*.
- PUSPITA, L. F. D. (2023). HUBUNGAN ANTARA TEKANAN DARAH DENGAN PENINGKATAN TEKANAN INTRA OKULER PADA PASIEN POLI MATA DI RSU ISLAM KLATEN TAHUN 2023. (*Doctoral Dissertation, UNIVERSITAS MUHAMMADIYAH KLATEN*).
- Pusvitasari, L. W., & Triningrat, A. A. M. P. (2015). Profil pasien glaukoma di Poliklinik Mata Rumah Sakit Indera Provinsi Bali Periode Januari 2014-Juni 2015. *METODE*.
- Putri, P. G. A. B., Sutyanawan, I. W. E., & Triningrat, A. M. P. (2018). Rumah Sakit Muhammadiyah Palembang Periode Januari 2017-April 2018. *E-Jurnal Medika Udayana*, 7(1), 16–21.
- Ramzy, I. (2019). Definition of hypertension and pressure goals during treatment (ESC-ESH Guidelines 2018). *E-Journal of Cardiology Practice*, 17(18).
- Rif'Ati, L., Halim, A., Lestari, Y. D., Moeloek, N. F., & Limburg, H. (2020). Blindness and Visual Impairment Situation in Indonesia Based on Rapid Assessment of Avoidable Blindness Surveys in 15 Provinces.

- <https://doi.org/10.1080/09286586.2020.1853178>, 28(5), 408–419.
<https://doi.org/10.1080/09286586.2020.1853178>
- Sakti, E. S., Budijanto, D., Widiyanti, W., Habibi, H., Prahastaz, A., Lestari, S., & Mildya, F. (2019). *InfoDATIN (Pusat Data dan Informasi Kementerian Kesehatan RI : Situasi Glaukoma di Indonesia)*. PUSDATIN KEMENKES RI.
- Saxena, R., Singh, D., & Vashist, P. (2013). Glaucoma: An Emerging Peril. *Indian Journal of Community Medicine : Official Publication of Indian Association of Preventive & Social Medicine*, 38(3), 135. <https://doi.org/10.4103/0970-0218.116348>
- Sherwood, L. (2016). *Fisiologi Manusia : Dari Sel ke Sistem* (8th ed.). EGC.
- Singh, J. N., Nguyen, T., Kerndt, C. C., & Dhamoon, A. S. (2023, January). *Physiology, Blood Pressure Age Related Changes*. Treasure Island (FL): StatPearls Publishing.
- Syuhada, R. (2016). HUBUNGAN TEKanan DARAH DENGAN PENINGKATAN TEKanan INTRAOKULI PADA PASIEN GLAUKOMA DI RSUD. Dr. H. ABUL MOELOEK TAHUN. *Jurnal Medika Malahayati*, 3(1), 35–37.
- Tham, Y. C., Li, X., Wong, T. Y., Quigley, H. A., Aung, T., & Cheng, C. Y. (2014). Global Prevalence of Glaucoma and Projections of Glaucoma Burden through 2040: A Systematic Review and Meta-Analysis. *Ophthalmology*, 121(11), 2081–2090. <https://doi.org/10.1016/J.OPHTHA.2014.05.013>
- Thayeb, D. A., Saerang, J. S. M., Rares, L. M., Manado, S. R., Kesehatan, B. I., Fakultas, M., & Universitas, K. (2013). PROFIL GLAUKOMA SEKUNDER AKIBAT KATARAK SENILIS PRE OPERASI DI RSUP. PROF. DR. R. D. KANDOU MANADO PERIODE JANUARI 2011 â€“ DESEMBER 2011. *EBiomedik*, 1(1). <https://doi.org/10.35790/EBM.V1I1.1163>
- Venkatesh, R., & Kavitha, S. (2016). Secondary angle closure glaucoma and malignant hypertension: a rare association. In *Ann Clin Case Rep.* (Vol. 1, Issue 1).
- Weinreb, R. N., Aung, T., & Medeiros, F. A. (2014). The Pathophysiology and Treatment of Glaucoma: A Review. *JAMA*, 311(18), 1901–1911. <https://doi.org/10.1001/JAMA.2014.3192>
- Weinreb, R. N., Leung, C. K. S., Crowston, J. G., Medeiros, F. A., Friedman, D. S., Wiggs, J. L., & Martin, K. R. (2016). Primary open-angle glaucoma. *Nature Reviews Disease Primers* 2016 2:1, 2(1), 1–19. <https://doi.org/10.1038/nrdp.2016.67>
- Wijaya, E. (2018). HUBUNGAN ANTARA DIABETES MILITUS DAN HIPERTENSI TERHADAP TERJADINYA GLAUKOMA DI RS.DR.AK.GANI PALEMBANG TAHUN 2017. *Prosiding Seminar Nasional Dan Penelitian Kesehatan 2018*, 1(1).
- Yadav, K. S., Rajpurohit, R., & Sharma, S. (2019). Glaucoma: Current treatment and impact of advanced drug delivery systems. *Life Sciences*, 221, 362–376. <https://doi.org/10.1016/J.LFS.2019.02.029>
- Yasukawa, T., Hanyuda, A., Yamagishi, K., Yuki, K., Uchino, M., Ozawa, Y., Sasaki, M., Tsubota, K., Sawada, N., Negishi, K., Tsugane, S., & Iso, H. (2022). Relationship between blood pressure and intraocular pressure in the JPHC-NEXT eye study. *Scientific Reports* 2022 12:1, 12(1), 1–8. <https://doi.org/10.1038/s41598-022-22301-1>

Zhao, D., Cho, J., Kim, M. H., & Guallar, E. (2014). The association of blood pressure and primary open-angle glaucoma: a meta-analysis. *American Journal of Ophthalmology*, 158(3).
<https://doi.org/10.1016/J.AJO.2014.05.029>

LAMPIRAN

Lampiran 1. Biodata Peneliti



Nama lengkap	Ratri Perdani Sahdin
Tempat, tanggal lahir	Palopo, 23 Maret 2001
Jenis Kelamin	Perempuan
Agama	Islam
Alamat	Pacellekang, Kabupaten Gowa
Fakultas	Kedokteran
Program Studi	Pendidikan Dokter Umum
NIM	C011201002
Nomor Telepon	081253844010
Alamat <i>e-mail</i>	ratriperdani@gmail.com
Riwayat Pendidikan	SDN 24 Temmalebba (2006-2012) SMPN 1 Palopo (2012-2015) SMAN 1 Palopo (2015-2018) S1 Fakultas Kedokteran Unhas (2020-2023)

Lampiran 2. Permohonan Izin Penelitian



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET, DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
PROGRAM STUDI SARJANA KEDOKTERAN

Jl. Perintis Kemerdekaan Km. 10 Tamalanrea, Makassar 90245, Telp. (0411) 587436, Fax. (0411) 586297

Nomor : 21019/UN4.6.8/PT.01.04/2023
Lamp : ---
Hal : **Permohonan Izin Penelitian**

1 September 2023

Kepada Yth. :
Direktur RSP Universitas Hasanuddin
Di-
Makassar

Dengan hormat, disampaikan bahwa mahasiswa Program Studi Pendidikan Dokter Fakultas Kedokteran Universitas Hasanuddin di bawah ini :

N a m a : Ratri Perdani Sahdin
N i m : C011201002


bermaksud melakukan penelitian di RSP Universitas Hasanuddin dengan judul penelitian **“Hubungan Tekanan Darah Dengan Tekanan Intraokuler Dan Jenis Glaukoma Pada Pasien Glaukoma Di Rs Unhas Tahun 2022”**

Sehubungan hal tersebut kiranya yang bersangkutan dapat diberi izin untuk melakukan Penelitian dalam rangka penyelesaian studinya.

Demikian permohonan kami, atas bantuan dan kerjasamanya disampaikan terima kasih.




Ketua,
Program Studi Sarjana Kedokteran
Fakultas Kedokteran Unhas



dr. Ririn Nislawati, M.Kes.,Sp.M
NIP 198101182009122003

Tembusan Yth :
L. Arsup

Lampiran 3. Surat Rekomendasi Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agusallim Bukhari, MMed, PhD, SpCK TELP. 081241850858, 0411 5780103, Fax : 0411-581431





REKOMENDASI PERSETUJUAN ETIK

Nomor : 664/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 11 September 2023



Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23080675	No Sponsor	
Peneliti Utama	Ratri Perdani Sahdin	Sponsor	
Judul Peneliti	Hubungan Tekanan Darah Dengan Tekanan Intraokular Dan Jenis Glaukoma Pada Pasien Glaukoma Di RS Unhas Tahun 2022		
No Versi Protokol	1	Tanggal Versi	8 September 2023
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 11 September 2023 sampai 11 September 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof. dr. Muh Nasrum Massi, PhD, SpMK(K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 4. Surat Izin Penelitian

 RUMAH SAKIT UNHAS	SURAT IZIN PENELITIAN	
	Nomor: 13974/UN4.24.1.1/PT.01.05/2023 (Perpanjangan 2)	Tanggal 29 November 2023
FORMULIR 03 PENDIDIKAN DAN PENELITIAN	Kepada Yth Kepala Instalasi Rekam Medik	
<p>Dengan hormat,</p> <p>Dengan ini menerangkan bahwa peneliti/ mahasiswa berikut ini:</p> <p>Nama : Ratri Perdani Sahdin</p> <p>NIM / NIP : C011201002</p> <p>Institusi/Universitas : Pendidikan Dokter, Fakultas Kedokteran, Universitas Hasanuddin, Makassar</p> <p>Kode penelitian : 230920_2</p> <p>Akan melakukan pengambilan data/ analisa bahan hayati:</p> <p>Terhitung : 24 Oktober 2023 s/d 21 Desember 2023</p> <p>Jumlah Subjek/Sample : 200</p> <p>Jenis Data : Data Sekunder : Data Rekam Medis Pasien Glaukoma Tahun 2022</p> <p>Untuk penelitian dengan judul: "Hubungan Tekanan Darah dengan Tekanan Intraokular dan Jenis Glaukoma pada Pasien Glaukoma di RS Unhas Tahun 2022"</p> <p>Harap dilakukan pembimbingan dan pendampingan seperlunya.</p> <p>Manager Pendidikan dan Penelitian,</p> <div style="display: flex; align-items: center;">  <div style="margin-left: 10px;"> <p>dr. Aslim Taslim, Sp.Onk.Rad, M.Kes NIP.198304252012121003</p> </div> </div> <p><small>Catatan: Lembaran ini diarsipkan oleh Admin Penelitian</small></p>		

Lampiran 5. Data Sekunder Pasien Glaukoma Rumah Sakit Unhas 2022

Nama Pasien	JK	U M U R	Riwayat Diabetes	Riwayat Hipertensi	Riwayat Obat	Visus	TIO		Tekanan Darah	Tekanan Darah			Jenis Glaukoma		CDR		VFI		SEVERITAS		VISUS
							KANAN	KIRI		Sistolik	Diastolik	MAP	Kanan	Kiri	Kanan	Kiri	Kanan	Kiri	Kanan	Kiri	
PASIEEN 46	L	51	0	1	Glauseta, KSR, Timolol	VOD : 20/60 VOS:NLP	28	45	110/70	110	70	83,33	PACG	PACG	0,9	1	3%		LANJUT	LANJUT	(Near-) Blindness
PASIEEN 101	P	50	0	0	0	VOD : NLP VOS : 1/300	61	54	140/80	140	80	100,00	PACG	PACG	1	1		35%	LANJUT	LANJUT	(Near-) Blindness
PASIEEN 105	L	76	0	0	0	VOD : 1/300 LP VOS : 1/300	14	27	110/70	110	70	83,33	PACG	PACG	0,3	0,3			RINGAN	RINGAN	(Near-) Blindness
PASIEEN 107	L	59	0	1	Amlodipine	VOD 20/80 PH 20/50 VOS : 5/60 PH (-)	17	20	150/90	150	90	110,00	PACS	PACG	0,3	0,3	90%	93%	RINGAN	RINGAN	Low Vision
PASIEEN 49	P	50	1	1	Amlodipine, Metformin, Timolol, Tafletan, Glauseta	VOD : 1/300 VOS : 20/30F	31	51	160/90	160	90	113,33	PACG	PACG	1	0,3		95%		RINGAN	(Near-) Normal Vision
PASIEEN 59	L	76	0	1	0	VOD : 20/100F (+2.00/-0,75 x 75) 20/40 VOS : LP	11	44	180/100	180	100	126,67	PACG	PACG	0,4	1	66%	2%	RINGAN	LANJUT	(Near-) Blindness
PASIEEN 47	L	68	0	1	Amlodipine	VOD : 1/300 VOS : 1/60 PH (-)	27	30	180/100	180	100	126,67	POAG	POAG	1	1			LANJUT	LANJUT	(Near-) Blindness
PASIEEN 36	L	61	0	0	0	VOD : 20/400 (-2.50/075 x 70) 20/40 PH (-) VOS : 1/300	20	46	130/80	130	80	96,67	POAG	POAG	0,3	0,8			RINGAN	LANJUT	(Near-) Blindness
PASIEEN 81	L	57	0	0	Glauseta, Timolol	VOD : 20/150 (-50/-3.50 x 90) = 20/30 VOS : 20/150 (-1.00/-2.50 x 90) = 20/40	17	20	140/70	140	70	93,33	POAG	POAG	0,8	0,8	44%	35%	LANJUT	LANJUT	Low Vision
PASIEEN 41	P	67	1	0	Metformin	VOD 1/2 /60 VOS : 1/300	15	26	140/90	140	90	106,67	POAG	POAG	0,8	0,8			LANJUT	LANJUT	(Near-) Blindness
PASIEEN 108	P	24	0	0	0	VOD : 1/300 PH (-) VOS : 2/60 PH (-)	5	6	110/60	110	60	76,67	POAG	POAG	0,5	0,7			RINGAN	SEDANG	Low Vision
PASIEEN 114	L	19	0	0	Floxa, Homatro, PCT, P-Pred	VOD : 20/25, VOS: nlp	56	51	100/70	100	70	80,00	POAG	POAG	0,5	0,8			RINGAN	LANJUT	(Near-) Blindness
PASIEEN 37	L	22	0	0	0	VOD : 20/20 PH 20/30 VOS : 2/60 PH 20/150	18	22	115/62	115	62	79,67		POAG	0,4	0,6				SEDANG	Low Vision

PASIEN 87	P	68	0	0	0	VOD : 20/120 (-2.00/1.00x90) 20/60F VOS : 1/300	10	50	150/80	150	80	103,33		POAG	0,3	1	76%		LANJUT	(Near-) Blindness	
PASIEN 113	L	46	0	0	Citicoline, Isotic Adreto	VOD : 20/30, VOS : 20/20	14	14	120/80	120	80	93,33		POAG	0,5	0,5			RINGAN	(Near-) Normal Vision	
PASIEN 15	L	12	1	0	Metformin	VOD : 20/150 PH 20/100 VOS : 1/300	28	13	110/60	110	60	76,67	POAG	POAG	0,3	1	87%		RINGAN	LANJUT	Low Vision
PASIEN 24	P	58	1	0	0	VODS : NLP	28	26	120/80	120	80	93,33	SACG	SACG	0,4	1			RINGAN	LANJUT	(Near-) Blindness
PASIEN 21	L	13	0	0	0	VOD : 20/60 VOS : NLP	38	51	110/70	110	70	83,33	SOAG	SACG	0,7	1	86%		SEDANG	LANJUT	(Near-) Blindness
PASIEN 86	P	53	1	0	Novorapid, Sansulin	VOD : 1/300 VOS :LP	48	50	110/70	110	70	83,33	SACG	SACG	0,3	0,3			RINGAN	RINGAN	(Near-) Blindness
PASIEN 18	L	60	0	0	Timolol	VOD : 5/60 PH 20/50 VOS : 1/300	18	18	120/90	120	90	100,00	SOAG	SACG	0,3	0,9			RINGAN	LANJUT	(Near-) Blindness
PASIEN 69	P	65	0	0	0	VOD : LP VOS: NLP	46	46	130/90	130	90	103,33	SACG	SACG	0,9	0,9				LANJUT	(Near-) Blindness
PASIEN 76	P	37	1	0	Glausetta, KSR, Timolo	VOD : 20/30 F PH (-) VOS :NLP	16	68	120/80	120	80	93,33		SACG	0,3	1				LANJUT	(Near-) Blindness
PASIEN 65	L	41	1	1	Amlodipine, Candesartan, Clonidine, Levemir, Novorapid	VOD : 20/80 PH 20/60	21	71	180/90	180	90	120,00		SACG	0,3	1				LANJUT	(Near-) Blindness
PASIEN 96	P	66	1	1	0	VOD : 20/60 VOS : NLP	13	39	190/67	190	67	108,00		SACG	0,3	1				LANJUT	(Near-) Blindness
PASIEN 97	L	54	1	1	0	VOD : 1/60 VOS :NLP	25	60	180/100	180	100	126,67		SACG	0,4	1				LANJUT	(Near-) Blindness
PASIEN 2	L	64	0	0	0	VOD : 20/40F PH 20/30. VOS : 1/2/60 (+10.00)1/60	17	15	100/70	100	70	80,00		SACG		0,3				RINGAN	(Near-) Blindness
PASIEN 48	L	42	0	1	Obat Hipertensi	VOD : 1/60 (+KM +8.00) VOS : NLP	20	26	130/80	130	80	96,67		SACG	0,5	1				LANJUT	(Near-) Blindness
PASIEN 68	P	92	1	0	0	VOD : 20/40 PH (-) VOS : NLP	8	41	130/70	130	70	90,00		SACG	0,9	0,9	30%			LANJUT	(Near-) Blindness

PASIEN 70	L	79	0	1	0	VOD : 20/40 VOS : NLP	14	45	160/90	160	90	113,33		SACG	0,3	0,5			RINGAN	(Near-) Blindness
PASIEN 74	L	59	0	1		Amlodipine, Candesartan	10	48	140/90	140	90	106,67		SACG	0,3	1			LANJUT	(Near-) Blindness
PASIEN 84	L	44	0	0	0	VOD : 20/20 VOS : 1/300	12	15	110/80	110	80	90,00		SACG	0,4	1			LANJUT	(Near-) Blindness
PASIEN 98	P	57	1	1		Amlodipine, Ryzodeg	17	60	125/80	125	80	95,00		SACG	0,3	1	92%		LANJUT	(Near-) Blindness
PASIEN 45	L	42	1	1		Amlodipine	20	50	140/80	140	80	100,00	SACG	SACG	0,4	1	55%		RINGAN	LANJUT (Near-) Blindness
PASIEN 35	L	62	0	1	0	VOD : 20/150 PH 20/100F VOS : 3/60	15	45	150/90	150	90	110,00	POAG	SOAG	0,5	0,5			RINGAN	RINGAN Low Vision
PASIEN 88	P	34	0	0		Lentikular Tetes Mata	28	38	100/70	100	70	80,00	SOAG	SOAG	0,5	0,5			RINGAN	RINGAN (Near-) Normal Vision
PASIEN 25	L	38	0	0	0	VOD: 20/120 VOS: 2/40F	16	20	130/80	130	80	96,67		SOAG	0,3	0,3	97%	98%		RINGAN Low Vision
PASIEN 80	L	14	0	0	0	VOD : 20/20 VOS : 1/60	16	26	100/60	100	60	73,33		SOAG	0,3	0,5				RINGAN (Near-) Blindness
PASIEN 106	P	58	1	1		Metformin, Timol, Hyaloph, Dorzolamide Glauseta	14	13	160/90	160	90	113,33		SOAG	0,3		95%	94%		RINGAN Low Vision
PASIEN 67	P	50	0	0	0	VOVS : NLP	28	26	130/70	130	70	90,00	PACG	PACG	1	1			LANJUT	LANJUT (Near-) Blindness
PASIEN 75	P	77	0	0	0	VOD : NLP VOS : 6/60	38	33	120/80	120	80	93,33	PACG	PACG	1	0,8		10%	LANJUT	LANJUT (Near-) Blindness
PASIEN 93	L	37	0	0	0	VOD : 20/50 PH(-) VOS : 20/40 PH 20/25	63	49	110/70	110	70	83,33	PACG	PACG	0,9	0,85	84%	99%	LANJUT	LANJUT (Near-) Normal Vision
PASIEN 92	L	73	0	1		Floxa, Glauseta, KSR, P-Pred, Timolol	43	21	185/86	185	86	119,00	PACG	PACG	0,9	0,9			LANJUT	(Near-) Blindness
PASIEN 100	L	75	0	1		Amlodipine	18	24	140/70	140	70	93,33	PACG	PACG	0,8	0,4	12%	83%	LANJUT	(Near-) Blindness

PASIEN 9	P	21	0	0	0	VOD : NLP VOS : 20/60	68	8	110/70	110	70	83,33	PACG	PACG	0,9	0,9		6%	LANJUT		(Near-) Blindness
PASIEN 7	L	67	0	0	Floxa, Glauca a, KSR, Na- dic, Timol, P Pred	VOD : 20/40 PH (-), VOS : NLP	17	3	110/70	110	70	83,33	PACG		0,5				RINGAN		(Near-) Normal Vision
PASIEN 82	L	54	1	0	0	VOD : 20/60 VOS : 20/20	48	15	120/80	120	80	93,33	PACG		0,6	0,3	88%	99%	SEDANG		(Near-) Normal Vision
PASIEN 118	P	59	1	1	Amlodipine, Candesartan, Clonidine, Furosemide	VOD : 1/60 VOS : 1/300	24	14	120/80	120	80	93,33	PACG		0,3	0,3			RINGAN		(Near-) Blindness
PASIEN 43	L	70	0	1	Amlodipine, Timolol	VOD : NLP VOS :20/40 PH 20/30 (+0.50/- 0.75 X 120) = 20/25	40	19	180/100	180	100	126,67	POAG	POAG	0,9	0,4			LANJUT	RINGAN	(Near-) Blindness
PASIEN 44	P	55	0	0	Timolol	VOD : 20/20 VOS : 1/300 PH (-)	21	22	160/90	160	90	113,33	POAG	POAG	0,3	0,3	63%	83%	RINGAN	RINGAN	(Near-) Normal Vision
PASIEN 53	L	59	0	1	Amlodipine	VOD : 20/30 F2 PH 20/25 VOS : 20/80 PH 20/30	15	14	130/80	130	80	96,67	POAG	POAG	0,7	0,5	98%	99%	SEDANG	RINGAN	(Near-) Normal Vision
PASIEN 111	L	77	0	0	Glauseta, KSR, Timolo	VOD : 20/60 PH 20/40F3 VOS : 20/40 F2 KM 20/30F1	19	16	158/83	158	83	108,00	POAG	POAG	0,6	0,6			SEDANG	SEDANG	(Near-) Normal Vision
PASIEN 63	L	37	0	0	0	VOD : NLP VOS : 1/300 PH (-)	51	43	100/80	100	80	86,67	POAG	POAG	0,9	0,7			LANJUT		(Near-) Blindness
PASIEN 110	P	62	0	0	CendoLyteer Citicoline, Timol	VOD : 20/40 PH 20/25 F2 VOS : 20/30 PH 20/20	38	25	180/90	180	90	120,00	POAG		0,8	0,3	3%	97%	LANJUT		(Near-) Normal Vision
PASIEN 60	L	57	0	1	Amlodipine	VOD : 20/30F PH 20/25 F VOS : 1/300	18	46	140/80	140	80	100,00	POAG	POAG	-	0,9	64%	92%	SEDANG		(Near-) Normal Vision
PASIEN 72	L	16	0	0	0	VOD : LP VOS : 2/60 KM 20/200	37	44	111/70	111	70	83,67	POAG	POAG	1	0,8			LANJUT		(Near-) Blindness
PASIEN 112	L	60	0	0	Flexa, Hyalub, Oculenta	VOD : 1/60 PH (-) VOS : 20/150 PH 20/50	48	42	50/22	140	90	106,67	POAG	POAG	1	0,3			LANJUT	RINGAN	(Near-) Blindness
PASIEN 58	P	46	1	1	Antasida, Glauseta, Glibenclamid e, KSR, LFX Metformin, Natrium Diclofenac, Timolol	VOD : 1/60 PH (-) VOS :20/20F	40	16	110/80	110	80	90,00	SACG	SACG	0,3	0,3			RINGAN	RINGAN	(Near-) Blindness

PASIEN 26	L	34	0	0	Glauset, KSR, Timol	VODS : NLP	41	14	110/70	110	70	83,33	SACG	EKSKLUSI	0,3	0,3			RINGAN	(Near-) Blindness
PASIEN 64	P	62	0	1	CendoLyteer Timol	VOD : NLP VOS : 1/60	47	61	140/90	140	90	106,67	SACG	PACG	1	0,7			LANJUT	(Near-) Blindness
PASIEN 16	L	47	0	0	0	VOD : 1/300, VOS : 20/20	49	10	110/70	110	70	83,33	SACG		0,9		29%	91%	LANJUT	(Near-) Blindness
PASIEN 19	L	24	0	0	0	VOD: 2/60 PH 20/400 (+10 — > -) VOS: 1/60 PH (-)	18	19	100/70	100	70	80,00	SACG		0,4				RINGAN	Low Vision
PASIEN 20	P	23	0	0	P-Pred, Hyalub, Methyl Prednisolone Glaucan, Timol	VOD: 1/60 VOS: 1/300	34	18	120/80	120	80	93,33	SACG		0,9				LANJUT	(Near-) Blindness
PASIEN 23	P	79	0	0	0	VOD : LP VOS : 20/60F PH (-)	24	10	110/80	110	80	90,00	SACG		0,3	0,3		1%	RINGAN	(Near-) Blindness
PASIEN 28	L	49	0	0	0	VOD : LP VOS : 20/20	52	19	130/80	130	80	96,67	SACG		0,3	0,3			RINGAN	(Near-) Blindness
PASIEN 79	P	67	0	0	0	VOD : 1/300 VOS :20/25F PH (-)	50	10	125/80	125	80	95,00	SACG		0,8	0,3			LANJUT	(Near-) Blindness
PASIEN 89	P	57	0	0	0	VOD : 1/300 VOS : 20/200 PH 20/40	30	16	130/80	130	80	96,67	SACG		0,5	0,3			RINGAN	(Near-) Blindness
PASIEN 95	P	67	1	1	Amlodipine, Metformin	VOD : LP VOS : 20/200 PH (-)	37	10	140/90	140	90	106,67	SACG		0,8	0,3			LANJUT	(Near-) Blindness
PASIEN 99	P	60	1	1	Amlodipine, Furosemide, Glimepirid	VOD : 2/60 PH (-) VOS : 20/100 (+2.25/- 0.75x90) 20/50	16	16	130/90	130	90	103,33	SACG		0,3	0,3			RINGAN	Low Vision
PASIEN 102	L	56	0	1	0	VOD : NLP VOS : 20/20 F2	81	18	180/110	180	110	133,33	SACG	EKSKLUSI	1	0,3		96%	LANJUT	(Near-) Blindness
PASIEN 17	L	34	0	0	0	VOD : 4/60 PH (-) VOS : 2/60 PH (-)	31	16	120/70	120	70	86,67	SOAG	SOAG	0,3	0,3			RINGAN	RINGAN Low Vision
PASIEN 29	L	59	0	0	0	VOD : 3/60 VOS : 20/150F PH -	29	19	120/80	120	80	93,33	SOAG	SOAG	0,8	0,8			LANJUT	LANJUT Low Vision

PASIEN 38	L	74	0	1	0	VOD : 3/60 PH 5/60 VOS : 1/300	30	18	130/90	130	90	103,33	SOAG	0,5	0,8			RINGAN	Low Vision
PASIEN 40	L	15	0	0	0	VOD : 1/300 VOS : 0.5 dec	23	14	110/60	110	60	76,67	SOAG	0,3	0,3			RINGAN	(Near-) Blindness
PASIEN 66	L	49	0	0	0	VOD : 1/300 VPS 20/80 PH 20/50	51	18	110/70	110	70	83,33	SOAG	0,6	0,3			SEDANG	(Near-) Blindness
PASIEN 83	P	58	1	1	Candesartan, Gabapentin, Glausetan, Insulin, KSR, Pirasetam, P- Pred, Timolol	VOD : 1/2 / 60 PH – VOS : 1/300	45	14	110/70	110	70	83,33	SOAG	0,9				LANJUT	(Near-) Blindness

Lampiran 6. Hasil Olah Data

TDS JENIS KELAMIN PEREMPUAN

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
TDS	29	100	190	131.72	21.847
JK = "P" (FILTER)	29	1	1	1.00	.000
Valid N (listwise)	29				

TDD JENIS KELAMIN PEREMPUAN

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
JK = "P" (FILTER)	29	1	1	1.00	.000
TDD	29	60.00	90.00	79.8966	8.59545
Valid N (listwise)	29				

MAP JENIS KELAMIN PEREMPUAN

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
JK = "P" (FILTER)	29	1	1	1.00	.000
MAP	29	76.67	120.00	97.1714	11.00853
Valid N (listwise)	29				

TDS JENIS KELAMIN LAKI-LAKI

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
JK = "L" (FILTER)	46	1	1	1.00	.000
TDS	46	100	185	131.28	26.255
Valid N (listwise)	46				

TDD JENIS KELAMIN LAKI LAKI

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
JK = "L" (FILTER)	46	1	1	1.00	.000
TDD	46	60.00	110.00	79.3696	11.87969
Valid N (listwise)	46				

MAP JENIS KELAMIN LAKI LAKI

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
JK = "L" (FILTER)	46	1	1	1.00	.000
MAP	46	31.33	133.33	95.0361	18.51884
Valid N (listwise)	46				

TDS VISUS NEAR NORMAL

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
VISUS = "(Near-) Normal Vision" (FILTER)	11	1	1	1.00	.000
TDS	11	110	190	140.00	23.345
Valid N (listwise)	11				

TDD VISUS NEAR NORMAL

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
VISUS = "(Near-) Normal Vision" (FILTER)	11	1	1	1.00	.000
TDD	11	62.00	90.00	77.1818	8.97572
Valid N (listwise)	11				

MAP VISUS NEAR NORMAL

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
VISUS = "(Near-) Normal Vision" (FILTER)	11	1	1	1.00	.000
MAP	11	79.67	113.33	98.1209	10.47187
Valid N (listwise)	11				

TDS VISUS NEAR BLIND

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
VISUS = "(Near-) Blindness" (FILTER)	51	1	1	1.00	.000
TDS	51	100	185	128.90	24.943
Valid N (listwise)	51				

TDD VISUS NEAR BLIND

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
VISUS = "(Near-) Blindness" (FILTER)	51	1	1	1.00	.000
TDD	51	60.00	100.00	78.4118	10.40803
Valid N (listwise)	51				

MAP VISUS NEAR BLIND

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
VISUS = "(Near-) Blindness" (FILTER)	51	1	1	1.00	.000
MAP	51	73.33	126.67	95.2414	14.51771
Valid N (listwise)	51				

TDS ADA DM

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
DM = " 1.00" (FILTER)	19	1	1	1.00	.000
TDS	19	110	190	136.58	25.715
Valid N (listwise)	19				

TDD ADA DM

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
DM = " 1.00" (FILTER)	19	1	1	1.00	.000
TDD	19	60.00	100.00	80.8947	10.14832
Valid N (listwise)	19				

MAP ADA DM

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
DM = " 1.00" (FILTER)	19	1	1	1.00	.000
MAP	19	76.67	126.67	99.4553	13.18273
Valid N (listwise)	19				

TD TIDAK ADA DM

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
DM = " .00" (FILTER)	56	1	1	1.00	.000
TDS	56	100	185	129.71	24.051
TDD	56	60.00	110.00	79.1250	10.89297
MAP	56	31.33	133.33	94.6425	16.76049
Valid N (listwise)	56				

TDS VISUS LOW

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
VISUS = "Low Vision" (FILTER)	13	1	1	1.00	.000
TDS	13	110	180	134.23	23.438
Valid N (listwise)	13				

TDD VISUS LOW

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
VISUS = "Low Vision" (FILTER)	13	1	1	1.00	.000
TDD	13	70.00	110.00	86.1538	11.20897
Valid N (listwise)	13				

MAP VISUS LOW

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
VISUS = "Low Vision" (FILTER)	13	1	1	1.00	.000
MAP	13	31.33	133.33	96.3838	24.48279
Valid N (listwise)	13				

TEKANAN DARAH ADA HT

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
TDS	28	110	190	148.93	25.106
TDD	28	67.00	110.00	86.5357	10.37976
MAP	28	83.33	133.33	107.3332	13.54821
HT = " 1.00" (FILTER)	28	1	1	1.00	.000
Valid N (listwise)	28				

TEKANAN DARAH TIDAK ADA HT

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
TDS	47	100	180	121.04	17.273
TDD	47	60.00	90.00	75.4255	8.53317
MAP	47	31.33	120.00	89.0277	13.24622
HT = " .00" (FILTER)	47	1	1	1.00	.000
Valid N (listwise)	47				

TD POAG

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
TDS	19	100	180	136.53	26.311
TDD	19	60.00	100.00	79.7368	12.09151
MAP	19	31.33	126.67	94.7026	22.06006
DD = "POAG" (FILTER)	19	1	1	1.00	.000
Valid N (listwise)	19				

TD PACG

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
TDS	15	110	185	133.00	25.621
TDD	15	70.00	100.00	78.4000	9.62734
MAP	15	83.33	126.67	96.5980	14.25225
DD = "PACG" (FILTER)	15	1	1	1.00	.000
Valid N (listwise)	15				

TD SOAG

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
TDS	11	100	160	121.82	19.400
TDD	11	60.00	90.00	75.4545	11.28152
MAP	11	73.33	113.33	90.9082	13.50603
DD = "SOAG" (FILTER)	11	1	1	1.00	.000
Valid N (listwise)	11				

TD TD TINGGI

TD SACC

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
TDS	30	100	190	131.00	24.509
TDD	30	67.00	110.00	81.5667	9.99201
MAP	30	80.00	133.33	98.0440	13.17393
DD = "SACC" (FILTER)	30	1	1	1.00	.000
Valid N (listwise)	30				

TD TIO NORMAL

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
TDS	17	100	160	126.94	19.080
TDD	17	60.00	90.00	77.2353	9.93434
MAP	17	76.67	113.33	93.8035	11.51671
TIO < 21 (FILTER)	17	1	1	1.00	.000
Valid N (listwise)	17				

TD ADA OBAT dan TIDAK ADA

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
TDS	37	100	185	136.16	24.455
TDD	37	60.00	100.00	81.8649	9.59792
MAP	37	31.33	126.67	97.9273	17.61797
OBAT = "Ada" (FILTER)	37	1	1	1.00	.000
Valid N (listwise)	37				

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
TDS	38	100	190	126.87	23.958
TDD	38	60.00	110.00	77.3421	11.30003
MAP	38	73.33	133.33	93.8505	14.16246
OBAT = "Tidak" (FILTER)	38	1	1	1.00	.000
Valid N (listwise)	38				

UJI NORMALITAS TDXTIO

One-Sample Kolmogorov-Smirnov Test

		Unstandardized Residual	
N		75	
Normal Parameters ^{a,b}	Mean	.0000000	
	Std. Deviation	15.9406990	
Most Extreme Differences	Absolute	.080	
	Positive	.080	
	Negative	-.078	
Test Statistic		.080	
Asymp. Sig. (2-tailed) ^c		.200 ^d	
Monte Carlo Sig. (2-tailed) ^e	Sig.	.276	
	99% Confidence Interval	Lower Bound	.265
		Upper Bound	.288

- Test distribution is Normal.
- Calculated from data.
- Lilliefors Significance Correction.
- This is a lower bound of the true significance.
- Lilliefors' method based on 10000 Monte Carlo samples with starting seed 299883525.

UJI HOMOGENITAS TDSXTIO

Box's Test of Equality of Covariance Matrices^a

Box's M	3.831
F	1.236
df1	3
df2	148451.485
Sig.	.295

Tests the null hypothesis that the observed covariance matrices of the dependent variables are equal across groups.

- Design: Intercept + JK

PEARSON TDS X TIO

Correlations

		TDS	TIO
TDS	Pearson Correlation	1	.200
	Sig. (2-tailed)		.086
	N	75	75
TIO	Pearson Correlation	.200	1
	Sig. (2-tailed)	.086	
	N	75	75

PEARSON TDS TIO (POAG)

Correlations

		TDS	TIO	DD = "POAG" (FILTER)
TDS	Pearson Correlation	1	.054	. ^a
	Sig. (2-tailed)		.825	.
	N	19	19	19
TIO	Pearson Correlation	.054	1	. ^a
	Sig. (2-tailed)	.825		.
	N	19	19	19
DD = "POAG" (FILTER)	Pearson Correlation	. ^a	. ^a	. ^a
	Sig. (2-tailed)	.	.	.
	N	19	19	19

- Cannot be computed because at least one of the variables is constant.

PEARSON TDDXTIO (POAG)

Correlations

		TIO	TDD	DD = "POAG" (FILTER)
TIO	Pearson Correlation	1	.335	. ^a
	Sig. (2-tailed)		.161	.
	N	19	19	19
TDD	Pearson Correlation	.335	1	. ^a
	Sig. (2-tailed)	.161		.
	N	19	19	19
DD = "POAG" (FILTER)	Pearson Correlation	. ^a	. ^a	. ^a
	Sig. (2-tailed)	.	.	.
	N	19	19	19

- Cannot be computed because at least one of the variables is constant.

PEARSON TIOXMAP (POAG)

Correlations

		TIO	MAP
TIO	Pearson Correlation	1	-.090
	Sig. (2-tailed)		.714
	N	19	19
MAP	Pearson Correlation	-.090	1
	Sig. (2-tailed)	.714	
	N	19	19

PEARSON TDSXTIO (PACG)

Correlations

		TIO	TDS
TIO	Pearson Correlation	1	-.008
	Sig. (2-tailed)		.976
	N	15	15
TDS	Pearson Correlation	-.008	1
	Sig. (2-tailed)	.976	
	N	15	15

PEARSON TDDXTIO (PACG)

Correlations

		TIO	TDD
TIO	Pearson Correlation	1	.059
	Sig. (2-tailed)		.836
	N	15	15
TDD	Pearson Correlation	.059	1
	Sig. (2-tailed)	.836	
	N	15	15

PEARSON MAPXTIO (PACG)

Correlations

		TIO	MAP
TIO	Pearson Correlation	1	.021
	Sig. (2-tailed)		.940
	N	15	15
MAP	Pearson Correlation	.021	1
	Sig. (2-tailed)	.940	
	N	15	15

PEARSON TDXTIO SOAG

Correlations

		TIO	TDS	TDD	MAP
TIO	Pearson Correlation	1	-.325	-.117	-.221
	Sig. (2-tailed)		.329	.732	.514
	N	11	11	11	11
TDS	Pearson Correlation	-.325	1	.864**	.960**
	Sig. (2-tailed)	.329		.001	.000
	N	11	11	11	11
TDD	Pearson Correlation	-.117	.864**	1	.970**
	Sig. (2-tailed)	.732	.001		.000
	N	11	11	11	11
MAP	Pearson Correlation	-.221	.960**	.970**	1
	Sig. (2-tailed)	.514	.000	.000	
	N	11	11	11	11

** . Correlation is significant at the 0.01 level (2-tailed).

PEARSON TD X TIO SACC

Correlations

		TIO	TDS	TDD	MAP
TIO	Pearson Correlation	1	.529**	.361*	.511**
	Sig. (2-tailed)		.003	.050	.004
	N	30	30	30	30
TDS	Pearson Correlation	.529**	1	.574**	.910**
	Sig. (2-tailed)	.003		.001	.000
	N	30	30	30	30
TDD	Pearson Correlation	.361*	.574**	1	.861**
	Sig. (2-tailed)	.050	.001		.000
	N	30	30	30	30
MAP	Pearson Correlation	.511**	.910**	.861**	1
	Sig. (2-tailed)	.004	.000	.000	
	N	30	30	30	30

** . Correlation is significant at the 0.01 level (2-tailed).

* . Correlation is significant at the 0.05 level (2-tailed).

PEARSON TDXTIO

Correlations

		TIO	TDS	TDD	MAP
TIO	Pearson Correlation	1	.200	.257*	.172
	Sig. (2-tailed)		.086	.026	.140
	N	75	75	75	75
TDS	Pearson Correlation	.200	1	.711**	.805**
	Sig. (2-tailed)	.086		.000	.000
	N	75	75	75	75
TDD	Pearson Correlation	.257*	.711**	1	.746**
	Sig. (2-tailed)	.026	.000		.000
	N	75	75	75	75
MAP	Pearson Correlation	.172	.805**	.746**	1
	Sig. (2-tailed)	.140	.000	.000	
	N	75	75	75	75

* . Correlation is significant at the 0.05 level (2-tailed).

** . Correlation is significant at the 0.01 level (2-tailed).

UJI NORMALITAS UNIVARIAT

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
TDS	.164	75	.000	.892	75	.000

a. Lilliefors Significance Correction

TDD UJI NORMALITAS

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
TDD	.175	75	.000	.927	75	.000

a. Lilliefors Significance Correction

MAP UJI NORMALITAS

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
MAP	.107	75	.035	.936	75	.001

a. Lilliefors Significance Correction

Kruskal-Wallis Test TDS X JENIS GLAUKOMA

Ranks

	JENIS	N	Mean Rank
TDS	POAG	19	42.79
	PACG	15	39.00
	SOAG	11	29.41
	SACG	30	37.62
	Total	75	

Test Statistics^{a,b}

TDS	
Kruskal-Wallis H	2.725
df	3
Asymp. Sig.	.436

a. Kruskal Wallis Test

b. Grouping Variable:
JENIS

Kruskal-Wallis Test TDD X JENIS GLAUKOMA

Ranks

	JENIS	N	Mean Rank
TDD	POAG	19	39.11
	PACG	15	35.10
	SOAG	11	30.73
	SACG	30	41.42
	Total	75	

Test Statistics^{a,b}

TDD	
Kruskal-Wallis H	2.439
df	3
Asymp. Sig.	.486

a. Kruskal Wallis Test

b. Grouping Variable:
JENIS

Kruskal-Wallis Test MAP X JENIS GLAUKOMA

Ranks

	JENIS	N	Mean Rank
MAP	POAG	19	38.32
	PACG	15	37.53
	SOAG	11	30.05
	SACG	30	40.95
	Total	75	

Test Statistics^{a,b}

MAP	
Kruskal-Wallis H	2.041
df	3
Asymp. Sig.	.564

a. Kruskal Wallis Test

b. Grouping Variable:
JENIS